CCL

Összesen 55 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM038217
Első szerző:Antman, Elliott M.
Cím:Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial : a randomised controlled trial / Elliott M. Antman, The Magnesium in Coronaries (MAGIC) Trial Investigators
Dátum:2002
ISSN:0140-6736
Megjegyzések:Background The benefits of supplemental administration of intravenous magnesium in patients with ST-elevation myocardial infarction (STEMI) are controversial. Despite promising results from work in animals and the ready availability of this simple, inexpensive treatment, conflicting results have been reported in clinical trials. Our aim was to compare short-term mortality in patients with STEMI who received either intravenous magnesium sulphate or placebo. Methods We did a randomised, double-blind trial in 6213 patients with acute STEMI who were assigned a 2 g intravenous bolus of magnesium sulphate administered over 15 min, followed by a 17 g infusion of magnesium sulphate over 24 h (n=3113), or matching placebo (n=3100). Our primary endpoint was 30-day all-cause mortality. At randomisation, patients were stratified by their eligibility for reperfusion therapy. The first stratum included patients who were aged 65 years or older and eligible for reperfusion therapy, and the second stratum included patients of any age who were not eligible for reperfusion therapy. Analysis was by intention-to-treat. Findings At 30 days, 475 (15.3%) patients in the magnesium group and 472 (15.2%) in the placebo group had died (odds ratio 1.0, 95% CI 0.9-1.2, p=0.96). No benefit or harm of magnesium was observed in eight prespecified subgroup analyses of patients and in 15 additional exploratory subgroup analyses. After adjustment for factors shown to effect mortality risk in a multivariate regression model, no benefit of magnesium was observed (1.0, 0.8-1.1, p=0.53). Interpretation Early administration of magnesium in high-risk patients with STEMI has no effect on 30-day mortality. In view of the totality of the available evidence, in current coronary care practice there is no indication for the routine administration of intravenous magnesium in patients with STEMI.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Lancet. - 360 : 9341 (2002), p. 1189-1196. -
További szerzők:Soltész Pál (1961-) (belgyógyász, kardiológus) The Magnesium in Coronaries (MAGIC) Trial Investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM027440
Első szerző:Balázs Csaba
Cím:Effect of ecogramostim on HLA class II antigen expression on thyrocytes / Csaba Balázs, Ágota Bokk, Edit Bodolay, Nadir R. Farid
Dátum:1991
ISSN:0140-6736
Tárgyszavak:Orvostudományok Klinikai orvostudományok szerkesztői levél
egyetemen (Magyarországon) készült közlemény
Megjelenés:Lancet. - 338 : 8778 (1991), 1344. p. -
További szerzők:Bokk Ágota Bodolay Edit (1950-) (belgyógyász, allergológus és klinikai immunológus) Farid, Nadir R.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM066524
Első szerző:Baselga, José
Cím:Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO) : a randomised, open-label, multicentre, phase 3 trial / José Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gómez, Phuong Dinh, Karine Fauria, Veerle Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horváth, Maria Coccia-Portugal, Julien Domont, Ling-Min Tseng, Georg Kunz, Joo Hyuk Sohn, Vladimir Semiglazov, Guillermo Lerzo, Marketa Palacova
Dátum:2012
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:The Lancet 379 (2012), p. 633-640. -
További szerzők:Bradbury, Ian Eidtmann, Holger Di Cosimo, Serena de Azambuja, Evandro Aura, Claudia Gómez, Henry Dinh, Phuong Fauria, Karine Van Dooren, Veerle Aktan, Gursel Goldhirsch, Aron Chang, Tsai-Wang Horváth Zsolt (1964-) (onkológus, belgyógyász, klinikai farmakológus) Coccia-Portugal, Maria Domont, Julien Tseng, Ling-Min Kunz, Georg Sohn, Joo Hyuk Semiglazov, Vladimir Lerzo, Guillermo Palacova, Marketa
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM082344
Első szerző:Butts, Charles
Cím:Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START) : a randomised, double-blind, phase 3 trial / Charles Butts, Mark A. Socinski, Paul L. Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor-Eliade Ciuleanu, Lionel Bosquée, José Manuel Trigo, Alexander Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Ernst Erich Eberhardt, Christoph Helwig, Andreas Schröder, Frances A. Shepherd, START trial team
Dátum:2014
ISSN:1470-2045
Megjegyzések:BACKGROUND: Effective maintenance therapies after chemoradiotherapy for lung cancer are lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in patients with stage III unresectable non-small-cell lung cancer when given as maintenance therapy after chemoradiation. METHODS: The phase 3 START trial was an international, randomised, double-blind trial that recruited patients with unresectable stage III non-small-cell lung cancer who had completed chemoradiotherapy within the 4-12 week window before randomisation and received confirmation of stable disease or objective response. Patients were stratified by stage (IIIA vs IIIB), response to chemoradiotherapy (stable disease vs objective response), delivery of chemoradiotherapy (concurrent vs sequential), and region using block randomisation, and were randomly assigned (2:1, double-blind) by a central interactive voice randomisation system to either tecemotide or placebo. Injections of tecemotide (806 ?g lipopeptide) or placebo were given every week for 8 weeks, and then every 6 weeks until disease progression or withdrawal. Cyclophosphamide 300 mg/m(2) (before tecemotide) or saline (before placebo) was given once before the first study drug administration. The primary endpoint was overall survival in a modified intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00409188. FINDINGS: From Feb 22, 2007, to Nov 15, 2011, 1513 patients were randomly assigned (1006 to tecemotide and 507 to placebo). 274 patients were excluded from the primary analysis population as a result of a clinical hold, resulting in analysis of 829 patients in the tecemotide group and 410 in the placebo group in the modified intention-to-treat population. Median overall survival was 25.6 months (95% CI 22.5-29.2) with tecemotide versus 22.3 months (19.6-25.5) with placebo (adjusted HR 0.88, 0.75-1.03; p=0.123). In the patients who received previous concurrent chemoradiotherapy, median overall survival for the 538 (65%) of 829 patients assigned to tecemotide was 30.8 months (95% CI 25.6-36.8) compared with 20.6 months (17.4-23.9) for the 268 (65%) of 410 patients assigned to placebo (adjusted HR 0.78, 0.64-0.95; p=0.016). In patients who received previous sequential chemoradiotherapy, overall survival did not differ between the 291 (35%) patients in the tecemotide group and the 142 (35%) patients in the placebo group (19.4 months [95% CI 17.6-23.1] vs 24.6 months [18.8-33.0], respectively; adjusted HR 1.12, 0.87-1.44; p=0.38). Grade 3-4 adverse events seen with a greater than 2% frequency with tecemotide were dyspnoea (49 [5%] of 1024 patients in the tecemotide group vs 21 [4%] of 477 patients in the placebo group), metastases to central nervous system (29 [3%] vs 6 [1%]), and pneumonia (23 [2%] vs 12 [3%]). Serious adverse events with a greater than 2% frequency with tecemotide were pneumonia (30 [3%] in the tecemotide group vs 14 [3%] in the placebo group), dyspnoea (29 [3%] vs 13 [3%]), and metastases to central nervous system (32 [3%] vs 9 [2%]). Serious immune-related adverse events did not differ between groups. INTERPRETATION: We found no significant difference in overall survival with the administration of tecemotide after chemoradiotherapy compared with placebo for all patients with unresectable stage III non-small-cell lung cancer. However, tecemotide might have a role for patients who initially receive concurrent chemoradiotherapy, and further study in this population is warranted.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Lancet Oncology. - 15 : 1 (2014), p. 59-68. -
További szerzők:Socinski, Mark A. Mitchell, Paul Thatcher, Nick Havel, Libor Krzakowski, Maciej Nawrocki, Sergiusz Ciuleanu, Tudor Bosquee, Lionel Trigo, José Manuel Spira, Alexander Tremblay, Lise Nyman, Jan Ramlau, Rodryg Wickart-Johansson, Gun Ellis, Peter Gladkov, Oleg Pereira, José Rodrigues Eberhardt, Wilfried Ernst Erich Helwig, Christoph Schröder, Andreas Shepherd, Frances A. Bittner Nóra (1963-) (orvos) START trial team
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM070733
Első szerző:Calverley, Peter M. A.
Cím:Roflumilast in symptomatic chronic obstructive pulmonary disease : two randomised clinical trials / Calverley P. M. A., Rabe K. F., Goehring Udo-Michael, Kristiansen S., Fabbri L. M., Martinez F. J., M2-124 and M2-125 study groups
Dátum:2010
ISSN:0140-6736
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:LANCET. - 374 : 9691 (2010), p. 685-694. -
További szerzők:Rabe, Klaus F. Goehring, Udo-Michael Kristiansen, Søren Fabbri, Leonardo M. Martinez, Fernando, J. Várkonyi István (1973-) (orvos) M2-124 and M2-125 study groups
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM120141
035-os BibID:(Scopus)85186449459
Első szerző:Chen-Xu, José
Cím:Subnational inequalities in years of life lost and associations with socioeconomic factors in pre-pandemic Europe, 2009-19 : an ecological study / José Chen-Xu, Orsolya Varga, Nour Mahrouseh, Terje Andreas Eikemo, Diana A. Grad, Grant M. A. Wyper, Andreea Badache, Mirza Balaj, Periklis Charalampous, Mary Economou, Juanita A. Haagsma, Romana Haneef, Enkeleint A. Mechili, Brigid Unim, Elena von der Lippe, Carl Michael Baravelli
Dátum:2024
ISSN:2468-2667
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:The Lancet Public Health. - 9 : 3 (2024), p. e166-e177. -
További szerzők:Varga Orsolya (1977-) (orvos, jogász) Mahrouseh, Nour (1993-) (Phd hallgató) Eikemo, Terje Andreas Grad, Diana Alecsandra Wyper, Grant M. A. Badache, Andreea Balaj, Mirza Charalampous, Periklis Economou, Mary Haagsma, Juanita A. Haneef, Romana Mechili, Enkeleint Aggelos Unim, Brigid Lippe, Elena von der Baravelli, Carl Michael
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM034117
Első szerző:Cohen, Alexander T.
Cím:Venous thromboembolism risk and prophylaxis int he avute hospital care setting (ENDORSE study) : a multinational cross-sectional study / Cohen A. T., Tapson V. F., Bergmann J. F., Goldhaber S. Z., Kakkar A. K., Deslandes B., Huang W., Zayaruzny M., Emery L., Anderson F. A. Jr., for the ENDORSE Investigators
Dátum:2008
ISSN:0140-6736
Megjegyzések:BACKGROUND: Information about the variation in the risk for venous thromboembolism (VTE) and in prophylaxis practices around the world is scarce. The ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) study is a multinational cross-sectional survey designed to assess the prevalence of VTE risk in the acute hospital care setting, and to determine the proportion of at-risk patients who receive effective prophylaxis. METHODS: All hospital inpatients aged 40 years or over admitted to a medical ward, or those aged 18 years or over admitted to a surgical ward, in 358 hospitals across 32 countries were assessed for risk of VTE on the basis of hospital chart review. The 2004 American College of Chest Physicians (ACCP) evidence-based consensus guidelines were used to assess VTE risk and to determine whether patients were receiving recommended prophylaxis. FINDINGS: 68 183 patients were enrolled; 30 827 (45%) were categorised as surgical, and 37 356 (55%) as medical. On the basis of ACCP criteria, 35 329 (51.8%; 95% CI 51.4-52.2; between-country range 35.6-72.6) patients were judged to be at risk for VTE, including 19 842 (64.4%; 63.8-64.9; 44.1-80.2) surgical patients and 15 487 (41.5%; 41.0-42.0; 21.1-71.2) medical patients. Of the surgical patients at risk, 11 613 (58.5%; 57.8-59.2; 0.2-92.1) received ACCP-recommended VTE prophylaxis, compared with 6119 (39.5%; 38.7-40.3; 3.1-70.4) at-risk medical patients. INTERPRETATION: A large proportion of hospitalised patients are at risk for VTE, but there is a low rate of appropriate prophylaxis. Our data reinforce the rationale for the use of hospital-wide strategies to assess patients' VTE risk and to implement measures that ensure that at-risk patients receive appropriate prophylaxis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Lancet. - 371 : 9610 (2008), p. 387-394. -
További szerzők:Tapson, Victor F. Bergmann, Jean-Francois Goldhaber, Samuel Z. Kakkar, Ajay K. Deslandes, Bruno Huang, Wei Zayaruzny, Maksim Emery, Leigh Anderson, Frederik A. Jr. Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) for the ENDORSE Investigators
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

8.

001-es BibID:BIBFORM107856
035-os BibID:(scopus)85092628373 (wos)000631354900021
Első szerző:Cunningham, Steve
Cím:Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children : a double-blind, randomised, placebo-controlled, phase 2b trial / Cunningham Steve, Piedra Pedro A., Martinon-Torres Federico, Szymanski Henryk, Brackeva Benedicte, Dombrecht Evelyne, Detalle Laurent, Fleurinck Carmen, RESPIRE Study Group
Dátum:2021
ISSN:2213-2600
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:The Lancet Respiratory Medicine. - 9 : 1 (2021), p. 21-32. -
További szerzők:Piedra, Pedro A. Martinon-Torres, Federico Szymanski, Henryk Brackeva, Benedicte Dombrecht, Evelyne Detalle, Laurent Fleurinck, Carmen Bene Zsolt (1981-) (orvos) RESPIRE Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM117248
035-os BibID:(cikkazonosító)100782 (Scopus)85178352005
Első szerző:de Jonge, Jeroen C.
Cím:Prevention of infections and fever to improve outcome in older patients with acute stroke (PRECIOUS) : a randomised, open, phase III, multifactorial, clinical trial with blinded outcome assessment / de Jonge Jeroen C., Sluis Wouter M., Reinink Hendrik, Bath Philip M., Woodhouse Lisa J., Zweedijk Berber, van de Beek Diederik, Aamodt Anne Hege, Alpers Iris, Ciccone Alfonso, Csiba Laszlo, Demotes Jacques, Korv Janika, Kurkowska-Jastrzebska Iwona, Dawson Jesse, Macleod Malcolm R., Ntaios George, Poli Sven, Milionis Haralampos, Ricci Stefano, Cenciarelli Silvia, Candelaresi Paolo, de Bruijn Sebastiaan F. T. M., Pathansali Rohan, Krishnan Kailash, Clarke Brian, Thomalla Götz, van der Worp H. Bart, PRECIOUS investigators
Dátum:2024
ISSN:2666-7762
Megjegyzések:Background: Infections and fever after stroke are associated with poor functional outcome or death. We assessed whether prophylactic treatment with anti-emetic, antibiotic, or antipyretic medication would improve functional outcome in older patients with acute stroke. Methods: We conducted an international, 2?2?2-factorial, randomised, controlled, open-label trial with blinded outcome assessment in patients aged 66 years or older with acute ischaemic stroke or intracerebral haemorrhage and a score on the National Institutes of Health Stroke Scale ? 6. Patients were randomly allocated (1:1) to metoclopramide (oral, rectal, or intravenous; 10 mg thrice daily) vs. no metoclopramide, ceftriaxone (intravenous; 2000 mg once daily) vs. no ceftriaxone, and paracetamol (oral, rectal, or intravenous; 1000 mg four times daily) vs. no paracetamol, started within 24 h after symptom onset and continued for four days. All participants received standard of care. The target sample size was 3800 patients. The primary outcome was the score on the modified Rankin Scale (mRS) at 90 days analysed with ordinal logistic regression and reported as an adjusted common odds ratio (an acOR < 1 suggests benefit and an acOR > 1 harm). This trial is registered (ISRCTN82217627). Findings: From April 2016 through June 2022, 1493 patients from 67 European sites were randomised to metoclopramide (n = 704) or no metoclopramide (n = 709), ceftriaxone (n = 594) or no ceftriaxone (n = 482), and paracetamol (n = 706) or no paracetamol (n = 739), of whom 1471 were included in the intention-to-treat analysis. Prophylactic use of study medication did not significantly alter the primary outcome at 90 days: metoclopramide vs. no metoclopramide (adjusted common odds ratio [acOR], 1.01; 95% CI 0.81?1.25), ceftriaxone vs. no ceftriaxone (acOR 0.99; 95% CI 0.77?1.27), paracetamol vs. no paracetamol (acOR 1.19; 95% CI 0.96?1.47). The study drugs were safe and not associated with an increased incidence of serious adverse events. Interpretation: We observed no sign of benefit of prophylactic use of metoclopramide, ceftriaxone, or paracetamol during four days in older patients with a moderately severe to severe acute stroke. Funding: This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No: 634809.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Fever
Infection
Intracerebral haemorrhage
Ischaemic stroke
Pneumonia
Stroke
Megjelenés:The Lancet Regional Health - Europe. - 36 (2024), p. 1-15. -
További szerzők:Sluis, Wouter M. Reinink, Hendrik Bath, Philip M. Woodhouse, Lisa J. Zweedijk, Berber van de Beek, Diederik Aamodt, Anne Hege Alpers, Iris Ciccone, Alfonso Csiba László (1952-) (neurológus, pszichiáter) Demotes-Mainard, Jacques Kõrv, Janika Kurkowska-Jastrzebska, Iwona Dawson, Jesse Macleod, Malcolm R. Ntaios, George Poli, Sven Milionis, Haralampos Ricci, Stefano Cenciarelli, Silvia Candelaresi, Paolo de Bruijn, Sebastiaan F. T. M. Pathansali, Rohan Krishnan, Kailash Clarke, Brian Thomalla, Götz van der Worp, H. Bart PRECIOUS investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM010690
Első szerző:Decramer, Marc
Cím:Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT) : a prespecified subgroup analysis of a randomised controlled trial / Marc Decramer, Bartolome Celli, Steven Kesten, Theodore Lystig, Sunil Mehra, Donald P. Tashkin, The UPLIFT Investigators
Dátum:2009
ISSN:0140-6736 (Print)
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Lancet. - 374 : 9696 (2009), p. 1171-1178. -
További szerzők:Celli, Bartolome Kesten, Steven Lystig, Theodore Mehra, Sunil Tashkin, Donald P. Szilasi Mária (1953-) (tüdőgyógyász, klinikai immunológus, allergológus, belgyógyász) The UPLIFT Investigators
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

11.

001-es BibID:BIBFORM046046
Első szerző:Diener, Hans-Christoph
Cím:Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) : randomised, double-blind, placebo-controlled trial / Diener Hans-Christoph, Bogousslavsky Julien, Brass Lawrence M, Cimminiello Claudio, Csiba Laszlo, Kaste Markku, Leys Didier, Matias-Guiu Jordi, Rupprecht Hans-Jürgen, the MATCH Investigators
Dátum:2004
ISSN:0140-6736
Megjegyzések:Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk subgroups of patients. We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit than clopidogrel alone in prevention of vascular events with potentially higher bleeding risk. METHODS: We did a randomised, double-blind, placebo-controlled trial to compare aspirin (75 mg/day) with placebo in 7599 high-risk patients with recent ischaemic stroke or transient ischaemic attack and at least one additional vascular risk factor who were already receiving clopidogrel 75 mg/day. Duration of treatment and follow-up was 18 months. The primary endpoint was a composite of ischaemic stroke, myocardial infarction, vascular death, or rehospitalisation for acute ischaemia (including rehospitalisation for transient ischaemic attack, angina pectoris, or worsening of peripheral arterial disease). Analysis was by intention to treat, using logrank test and a Cox's proportional-hazards model. FINDINGS: 596 (15.7%) patients reached the primary endpoint in the group receiving aspirin and clopidogrel compared with 636 (16.7%) in the clopidogrel alone group (relative risk reduction 6.4%, [95% CI -4.6 to 16.3]; absolute risk reduction 1% [-0.6 to 2.7]). Life-threatening bleedings were higher in the group receiving aspirin and clopidogrel versus clopidogrel alone (96 [2.6%] vs 49 [1.3%]; absolute risk increase 1.3% [95% CI 0.6 to 1.9]). Major bleedings were also increased in the group receiving aspirin and clopidogrel but no difference was recorded in mortality. INTERPRETATION: Adding aspirin to clopidogrel in high-risk patients with recent ischaemic stroke or transient ischaemic attack is associated with a non-significant difference in reducing major vascular events. However, the risk of life-threatening or major bleeding is increased by the addition of aspirin.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Lancet. - 364 : 9431 (2004), p. 331-337. -
További szerzők:Bogousslavsky, Julien Brass, Lawrence M. Cimminiello, Claudio Csiba László (1952-) (neurológus, pszichiáter) Kaste, Markku Leys, Didier Matias-Guiu, Jordi Rupprecht, Hans-Jürgen the MATCH Investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM115545
035-os BibID:(scopus)85174452176
Első szerző:Distler, Oliver
Cím:Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc) : open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial / Distler Oliver, Allanore Yannick, Denton Christopher P., Kuwana Masataka, Matucci-Cerinic Marco, Pope Janet E., Atsumi Tatsuya, Becvár Radim, Czirják László, Hachulla Eric, Ishii Tomonori, Ishikawa Osamu, Johnson Sindhu R., De Langhe Ellen, Stagnaro Chiara, Riccieri Valeria, Schiopu Elena, Silver Richard M., Smith Vanessa, Steen Virginia, Stevens Wendy, Szücs Gabriella, Truchetet Marie-Elise, Wosnitza Melanie, Laapas Kaisa, Kramer Frank, Khanna Dinesh
Dátum:2023
ISSN:2665-9913
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Lancet Rheumatology. - 5 : 11 (2023), p. e660-e669. -
További szerzők:Allanore, Yannick Denton, Christopher Kuwana, Masataka Matucci-Cerinic, Marco Pope, Janet Atsumi, Tatsuya Becvar, Radim Czirják László Hachulla, Eric Ishii, Tomonori Ishikawa, Osamu Johnson, Sindhu R. De Langhe, Ellen Stagnaro, Chiara Riccieri, Valeria Schiopu, Elena Silver, Richard Smith, Vanessa Steen, Virginia Stevens, Wendy Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Truchetet, Marie-Elise Wosnitza, Melanie Laapas, Kaisa Kramer, Frank Khanna, Dinesh
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 3 4 5 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.